I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| B cell | 6 studies | 29% ± 3% | |
| T cell | 6 studies | 35% ± 8% | |
| plasmablast | 5 studies | 38% ± 17% | |
| erythrocyte | 5 studies | 31% ± 12% | |
| transit amplifying cell | 4 studies | 26% ± 8% | |
| pro-B cell | 4 studies | 29% ± 6% | |
| CD8-positive, alpha-beta T cell | 4 studies | 35% ± 11% | |
| abnormal cell | 3 studies | 17% ± 1% | |
| plasma cell | 3 studies | 28% ± 3% | |
| erythroblast | 3 studies | 48% ± 22% | |
| precursor B cell | 3 studies | 50% ± 20% | |
| natural killer cell | 3 studies | 30% ± 4% | |
| CD4-positive, alpha-beta T cell | 3 studies | 46% ± 15% |
